(Q35617263)

9 August 2017

title

Differences of the Fecal Microflora With Clostridium difficile Therapies (English)

1 reference

9 August 2017

0 references

Clostridium difficile

0 references

author name string

Thomas J Louie

1

1 reference

9 August 2017

Brendan Byrne

2

1 reference

9 August 2017

Judith Emery

3

1 reference

9 August 2017

Linda Ward

4

1 reference

9 August 2017

Wally Krulicki

5

1 reference

9 August 2017

David Nguyen

6

1 reference

9 August 2017

Kaiyu Wu

7

1 reference

9 August 2017

Kristine Cannon

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

Clinical Infectious Diseases

9 August 2017

published in

1 reference

9 August 2017

volume

60 Suppl 2

1 reference

9 August 2017

page(s)

S91-7

1 reference

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

A new strategy for the prevention of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Spore formation and toxin production in Clostridium difficile biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Is primary prevention of Clostridium difficile infection possible with specific probiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV252

21 January 2018

Identifiers

DOI

10.1093/CID/CIV252

1 reference

9 August 2017

1 reference